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Abstract
This study investigated the relationship between erythrocyte membrane fatty acid (FA) lev-
els and the severity of symptoms of individuals at ultra-high risk (UHR) for psychosis. Sub-
jects of the present study consisted of 80 neuroleptic-naïve UHR patients. Partial
correlation coefficients were calculated between baseline erythrocyte membrane FA levels,
measured by gas chromatography, and scores on the Positive and Negative Syndrome
Scale (PANSS), Global Assessment of Functioning Scale, and Montgomery–Asberg
Depression Rating Scale (MADRS) after controlling for age, sex, smoking and cannabis
use. Subjects were divided into three groups according to the predominance of positive or
negative symptoms based on PANSS subscale scores; membrane FA levels in the three
groups were then compared. More severe negative symptoms measured by PANSS were
negatively correlated with two saturated FAs (myristic and margaric acids), oneω-9 mono-
unsaturated FA (MUFA; nervonic acid), and oneω-3 polyunsaturated FA (PUFA; docosa-
pentaenoic acid), and were positively correlated with twoω-9 MUFAs (eicosenoic and
erucic acids) and twoω-6 PUFAs (γ-linolenic and docosadienoic acids). More severe posi-
tive symptoms measured by PANSS were correlated only with nervonic acid. No associa-
tions were observed between FAs and MADRS scores. In subjects with predominant
negative symptoms, the sum of theω-9 MUFAs and theω-6:ω-3 FA ratio were both signifi-
cantly higher than in those with predominant positive symptoms, whereas the sum ofω-3
PUFAs was significantly lower. In conclusion, abnormalities in FA metabolism may contrib-
ute to the neurobiology of psychopathology in UHR individuals. In particular, membrane FA
alterations may play a role in negative symptoms, which are primary psychopathological
manifestations of schizophrenia-related disability.
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Introduction
Schizophrenia is a severe mental illness that typically begins in adolescence or early adult life. It
is a heterogeneous disorder with diverse symptoms which are generally characterised as posi-
tive or negative [1,2]. Positive symptoms, such as delusions and hallucinations, are considered
to be more transient; negative symptoms, such as blunting of affect and passive withdrawal, are
regarded as more persistent and contribute more to impairment [3].
The dopamine hypothesis is one of the most influential theories about the etiology of
schizophrenia. Initially, the hypothesis emphasised an etiologic role of hyperdopaminergia, but
this was subsequently reconceptualised to specify subcortical hyperdopaminergia with prefron-
tal hypodopaminergia [4]. Normally, the prefrontal dopamine system suppresses the limbic
dopamine system; however, in schizophrenia, this suppression seems to be reduced due to dis-
turbed prefrontal dopaminergic activity, leading to elevated limbic dopaminergic activity [5].
The dopamine hypothesis is concordant with both the negative symptoms of schizophrenia,
likely linked with prefrontal hypodopaminergia, and the positive symptoms, strongly related to
enhanced limbic dopaminergic activity [6].
While psychopathology is traditionally explained by disturbed neurotransmitter function,
polyunsaturated fatty acids (PUFAs) gained interest in terms of the etiology of structural and
functional abnormalities of the developing nervous system in schizophrenia. PUFAs are major
constituents of neuronal and myelin membranes but have also important functions in the regu-
lation of neuronal migration, pruning, and synaptic plasticity. Evidence from animal studies
shows that a profound experimental ω-3 PUFA deficiency can alter dopaminergic and seroto-
nergic neurotransmitter systems. These associations between PUFA status and neurotransmis-
sion may explain the role of PUFAs on human brain function and behaviour [7]. PUFAs are
also selectively concentrated in synaptic neuronal membranes and regulate vascular and
immune functions that affect the central nervous system [8]. The ω-3 PUFAs have anti-inflam-
matory effects, suppress interleukin-1β, tumor necrosis factor-α and interleukin-6, whereas ω-
6 PUFAs do not [9]. A positive correlation between ω-6 PUFAs and intracellular phospholi-
pase-2 (inPLA2) activity was observed in patients at ultra-high risk (UHR) for psychosis, while
supplementation with ω-3 PUFA resulted in a significant decrease in inPLA2 activity [10].
These potential pro-inflammatory effects of ω-6 PUFAs and anti-inflammatory effects of ω-3
PUFAs may be associated with psychopathology in different way.
The accumulated evidence suggests that patients with schizophrenia are deficient in key
PUFAs [11]. However, it is not clearly understood which PUFAs are altered and how PUFA
deficiencies relate to psychotic symptoms. Several studies have demonstrated an association
between PUFA deficiencies and the severity of the negative symptoms of schizophrenia,
whereas others have reported inconsistent findings [12–14]. It is also not known if PUFA alter-
ations reflect risk factors such as nutrition, are a result of a biological predisposition to schizo-
phrenia or if they are associated only with an existing psychotic state, where they might be
influenced by disease related pathways such as oxidative damage to lipids [14]. As antipsy-
chotic medication and also the progression of illness may alter PUFA levels, FA research
focussed on drug-free first-episode patients to minimise this confound. Evaluations of PUFA
profiles in individuals at the prodromal (UHR) stage of schizophrenia will help even more to
clarify the role of FAs in schizophrenia etiopathogenesis.
Recently, α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and ω-6 PUFAs were found
to be significantly lower in young UHR individuals than in healthy controls [15]. This suggests
that FA deficiency may be present prior to illness onset and may be useful as a potential risk
biomarker for the high-risk state, using the classification of Davis [16]. To investigate state
marker properties, the present exploratory study aimed to investigate the relationship between
Fatty Acids and Psychopathology in the Vienna Omega-3 Study
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erythrocyte membrane FA levels and the severity of symptoms in individuals at UHR for psy-
chosis. The association between membrane FAs and psychotic symptoms was also evaluated
according to the predominance of positive or negative symptoms.
Methods
Subjects
The study sample consisted of 81 antipsychotic-naïve UHR individuals aged 13–25 years
involved in a randomised controlled trial of ω-3 FA supplementation (clinicaltrials.gov identi-
fier: NCT00396643) [17]. Participants were recruited from the psychosis detection unit at the
Medical University of Vienna, Austria. Levels of erythrocyte membrane FAs were determined
in 80 participants at baseline. All study subjects met one or more of the three operationally
defined and validated UHR criteria: attenuated positive psychotic symptoms, transient psycho-
sis, and genetic risk plus a decrease in functioning [18]. These criteria comprise a combination
of trait and state factors that identify people whose risk of becoming psychotic may approach
40% within a 12-month period [19,20]. The presence of attenuated psychotic symptoms and
transient psychosis were determined in a semi-structured interview applying Positive and Neg-
ative Syndrome Scale (PANSS) [21] cut off scores for symptom severity proposed by Morrison
et al [22] and frequency and duration criteria by Yung et al [19]. Genetic risk was composed of
individuals who had a schizotypal personality disorder or a family history of psychotic disorder
in a first-degree relative (as assessed with the Family History Research Diagnostic Criteria)
[23] and a decrease of functioning of 30% or more on the Global Assessment of Functioning
(GAF) Scale [24] within the past year. Exclusion criteria included a history of a previous psy-
chotic disorder or manic episode, substance-induced psychotic disorder, acute suicidal or
aggressive behaviour, current DSM-IV [24] diagnosis of substance dependence (except canna-
bis dependence), neurological disorders, or IQ less than 70. People with gross structural brain
abnormalities observable on their magnetic resonance image (MRI) scan were excluded. Also
excluded were people who had previous treatment with an antipsychotic or mood-stabilizing
agent for more than one week and people who had taken omega-3 PUFA supplements within 8
weeks of being included in the trial. Finally, people showing laboratory values more than 10%
outside the normal range for transaminases, thyroid hormones, C-reactive protein, or bleeding
parameters were excluded.
The study was carried out according to the latest version of the Declaration of Helsinki and
was approved by the Medical University of Vienna Ethics Committee. Written informed con-
sent was obtained from all participants (written consent of parent or guardian was obtained for
those aged< 18 years). [25]
Analysis of erythrocyte membrane FA composition
Erythrocyte membrane phospholipid composition closely reflects that of neuronal membranes
and provides an easily accessible indicator of brain phospholipids [26,27]. We separated
plasma and erythrocytes from whole blood samples and analysed the FA composition in the
phospholipids of the phosphatidylethanolamine (PE) fraction of erythrocyte membranes. Fatty
acid containing erythrocyte membrane extracts were evaporated, and phospholipid fractions
were dissolved using thin-layer gas chromatography (50 ml chloroform, 37.5 ml methanol, 3.5
ml glacial acetic acid, and 2 ml distilled water). Phospholipid fractions were then saponified
and esterified [28–30].
The PE fraction, which contains mono- and polyunsaturated fatty acids, is situated largely
on the inner side of membranes. The presumed pathology underlying phospholipid alterations
in psychotic illness includes increased peroxidation (i.e., oxidative stress) leading to increased
Fatty Acids and Psychopathology in the Vienna Omega-3 Study
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oxidative damage of PUFA, all related to ongoing excitotoxicity. This pathology particularly
affects the cytosolic (inner) side of cell membranes. As PE is the most common phospholipid
on the inner side of membranes in the brain, the FA levels (in mol% of total fatty acid levels) of
this PE fraction were included in our statistical analysis. Additional analysis details are pre-
sented in a previous study [10].
Using gas chromatography and standard quantitation methods, values for the following
classes of FAs were obtained: saturated FAs (14:0, 16:0, 17:0, 18:0); monounsaturated (MU)
FAs (18:1ω-9, 20:1ω-9, 20:3ω-9, 22:1ω-9, 24:1ω-9), ω-6 PUFAs (18:2ω-6, 18:3ω-6, 20:3ω-6,
20:4ω-6, 22:2ω-6, 22:4ω-6), and ω-3 PUFAs (18:3ω-3, 20:5ω-3, 22:5ω-3, 22:6ω-3).
Psychiatric outcome measures
Psychotic symptom severity was assessed using the PANSS, which has been widely used to
measure psychotic symptoms with good validity and reliability [21,31,32]. The PANSS consists
of three subscales (positive, negative, and general psychopathology) and is used to classify
patients with schizophrenia as dominant positive symptoms, dominant negative symptoms, or
mixed type. Subjects were divided into three groups according to the predominance of positive
or negative symptoms, which was determined based on PANSS positive and negative subscale
scores. Positive symptom predominance was defined as a score of 2 or higher on the positive
subscale relative to the negative subscale. Negative symptom predominance was defined as a
score of 2 or higher on the negative subscale relative to the positive subscale. Mixed type was
defined as: -1 positive minus negative subscale score 1.
The GAF scale was used to measure social, occupational, and psychological functioning
[24,33]. The GAF is an analogue scale (0–100), with higher scores indicating better functioning.
The Montgomery–Asberg Depression Rating Scale (MADRS) was used to assess depressive
symptoms [34]. Subjects were evaluated by experienced clinicians (raters) who were trained to
administer these tools. Inter-rater reliability estimates were high (intra-class correlation
coefficients> 0.92). Cronbach’s alpha values for the PANSS and MADRS in this study were
0.849 and 0.885, respectively.
Statistical analysis
Partial correlation coefficients were calculated between membrane FA levels and scores on the
PANSS (total score and scores on the three subscales), MADRS, and GAF after controlling for
age, sex, smoking and cannabis use. Levels of FAs including the sum of MUFAs, ω-6 PUFAs,
and ω-3 PUFAs; and the ω-6:ω-3 FA ratios were compared among the three PANSS subgroups
(dominant positive symptoms, dominant negative symptoms, and mixed type) using analysis
of variance (ANOVA) followed by post hoc Bonferroni’s tests. All statistical tests were two-
tailed, with a significance level of P<0.05.
Results
Partial correlations between erythrocyte membrane PE fatty acids and symptom severity mea-
sures after controlling for age, sex, smoking, cannabis use, and scores on MADRS and GAF are
presented in Table 1. The ω-6:ω-3 FA ratio was positively correlated with PANSS total and neg-
ative symptom scores and sum of the ω 3 fatty acids was negatively associated with PANSS neg-
ative symptom scores. Total PANSS scores were negatively correlated with two saturated FAs
(myristic and margaric acids) and one ω-9 MUFA (nervonic acid) and positively correlated
only with two ω-9 MUFAs (eicosenoic and erucic acids) and two ω-6 PUFAs (γ-linolenic and
docosadienoic acids). PANSS positive symptom scores were significantly correlated with ner-
vonic acid. In terms of PANSS negative symptom and general psychopathology scores, negative
Fatty Acids and Psychopathology in the Vienna Omega-3 Study
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correlations were found with two saturated FAs (myristic and margaric acids) and one ω-9
MUFA (nervonic acid), whereas positive correlations were found with two ω-9 MUFAs (eico-
senoic and erucic acids) and two ω-6 PUFAs (γ-linolenic and docosadienoic acids). One ω-3
PUFA (docosapentaenoic acid, (DPA)) was negatively correlated with PANSS negative symp-
toms scores. GAF scores were correlated with one ω-6 PUFA (docosadienoic acid).
Demographic and clinical characteristics of subgroups according to PANSS scores are
shown in Table 2. No significant differences were found with regard to age; sex; use of alcohol,
cannabis, tobacco, or any illicit drug; MADRS scores; or transition to psychosis. GAF scores
were significantly lower in the negative-symptoms-dominant group than in the positive-symp-
toms-dominant group (p-value = 0.004, ANOVA post-hoc analysis).
Table 3 include the results of group comparison of FA levels among the three PANSS sub-
groups. The sum of ω-3 PUFAs and myristic acid levels were significantly lower in the nega-
tive-symptoms-dominant group than in the positive-symptoms-dominant group. The sum of
the ω-9 MUFAs and two single ω-9 MUFAs (eicosenoic and erucic acids), two ω-6 PUFAs (γ-
Table 1. Partial correlations coefficients between erythrocyte membrane phosphatidylethanolamine lipids and psychiatric measures controlling
for age, sex, smoking, and cannabis use.
PANSS MADRS GAF
Total Positive Negative General
Myristic acid (14:0) -.305** -.085 -.301** -.297** -.177 .176
Palmitic acid (16:0) -.167 -.082 -.196 -.120 -.027 -.017
Margaric acid (17:0) -.260* .058 -.333** -.249* .051 .069
Stearic acid (18:0) .085 -.083 .101 .119 .008 -.085
Oleic acid (18:1n-9) -.029 .047 .030 .010 .106 .023
Eicosenoic acid (20:1n-9) .378*** .128 .478*** .268* -.004 -.193
Mead acid (20:3n-9) .198 .052 .205 .187 .124 -.043
Erucic acid (22:1n-9) .395*** .158 .446*** .314** .072 -.182
Nervonic acid (24:1n-9) -.339** -.231* -.277* -.316** -.185 .108
Linoleic acid (18:2n-6) -.019 -.063 .006 -.012 -.012 .044
γ-Linolenic acid (18:3n-6) .332** .109 .383*** .268* .160 -.139
Dihomo-γ-linolenic acid (20:3n-6) -.029 -.128 .081 -.066 -.108 .202
Arachidonic acid (20:4n-6) -.030 .046 -.036 -.049 -.080 .073
Docosadienoic acid (22:2n-6) .388*** .118 .428*** .336** .096 -.247*
Adrenic acid (22:4n-6) .104 .104 .108 .061 -.088 -.082
α-Linolenic acid (18:3n-3) -.074 -.131 -.079 -.015 -.157 .126
Eicosapentaenoic acid (20:5n-3) -.085 .004 -.149 -.040 .144 .039
Docosapentaenoic acid (22:5n-3) -.215 -.052 -.267* -.165 -.088 .199
Docosahexaenoic acid (22:6n-3) -.075 .072 -.173 -.031 .058 .070
Sum of monounsaturated fatty acids .184 .098 .220 .125 .100 -.051
Sum of polyunsaturated fatty acids -.028 .031 -.035 -.039 -.078 .103
Sum of n-6 fatty acids .022 .028 .051 -.013 -.102 .069
Sum of n-3 fatty acids -.146 .021 -.239* -.089 .017 .133
n-6 to n-3 fatty acids ratio .232* .057 .305** .165 .052 -.189
* p-value < 0.05
** p-value < 0.01
*** p-value < 0.001
PANSS, Positive and Negative Syndrome Scale; MADRS, Montgomery–Asberg Depression Rating Scale’ GAF, Global Assessment of Functioning
doi:10.1371/journal.pone.0151417.t001
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linolenic and docosadienoic acids), and the ω-6:ω-3 FA ratio were all significantly higher in the
negative-symptoms-dominant as compared to the positive-symptoms-dominant group.
Discussion
In this exploratory study of individuals at UHR for psychosis, the PE fraction of erythrocyte
membrane FAs were associated with severity of psychopathology. Negative symptoms were
negatively associated with saturated FAs (myristic and margaric acids), ω-3 PUFA (DPA), and
nervonic acid but positively associated with several other ω-9 MUFAs (eicosenoic and erucic
acids) and ω-6 PUFAs (γ-linolenic and docosadienoic acids). The sum of the ω-9 MUFAs and
the ω-6:ω-3 FA ratio were both significantly higher, whereas the sum of the ω-3 PUFAs was
significantly lower in subjects with predominant negative symptoms compared with those with
predominant positive symptoms. No associations were observed between FAs and MADRS
scores, suggesting that the associations between FAs and negative symptoms were not con-
founded by depression, a potential concern given their overlapping phenomenology. To the
best of our knowledge, this is the first study conducted in neuroleptic-naïve UHR subjects that
has demonstrated a relationship between membrane FA levels and the severity of symptom-
atology. The findings suggest that cell membrane lipid biology may be useful to assess during
the onset phase of psychotic disorders and are consistent with the observation that supplemen-
tation with omega-3 PUFAs might be an effective and longer-term preventive treatment in this
cohort of UHR patients [17,35].
Our findings of an association between membrane FA level and negative symptoms are
comparable to earlier studies conducted in patients with schizophrenia. Glen and colleagues
found that patients with predominantly negative symptoms exhibited lower levels of ω-3
PUFAs in red blood cells compared with those with persistently positive symptoms and con-
trols [12]. Additionally, patients with low erythrocyte PUFA (sum of ω-3 and ω-6 FA levels)
Table 2. Comparison of demographic and clinical characteristics of participants according to dominance of positive or negative symptoms.
Total Subtypes
(n = 80) Positive dominant[a] (N = 38) Mixed[b] (N = 23) Negative dominant[c] (N = 19) p value
Sex, female, n 54 (67.5) 26 (68.4) 16 (69.6) 12 (60.0) 0.764
Age, years, mean (SD) 16.5 (2.1) 16.6 (2.2) 16.6 (2.7) 16.1 (1.3) 0.651
Alcohol 0.949
Less than weekly 45 (56.3) 22 (57.9) 12 (52.2) 12 (60.0)
1–6 drinks per week 21 (26.3) 10 (26.3) 7 (30.4) 4 (20.0)
Daily 14 (17.5) 6 (15.8) 4 (17.4) 4 (20.0)
Cannabis 0.410
No 68 (85.0) 33 (93.5) 19 (82.6) 17 (85.0)
 2g per week 8 (10.0) 2 (6.5) 4 (17.4) 2 (10.0)
> 2g per week 4 (5.0) 3 (0.0) 0 (7.7) 1 (5.0)
Smoking, yes, n (%) 42 (52.5) 17 (45.2) 12 (50.0) 13 (65.2) 0.340
Any illicit drug, n (%) 14 (17.5) 6 (9.7) 4 (15.4) 4 (30.4) 0.922
Transition, yes, n (%) 13 (16.3) 4 (10.5) 4 (17.4) 5 (25.0) 0.353
MADRS, score, mean (SD) 18.2 (8.8) 16.0 (8.2) 20.9 (9.8) 19.2 (7.9) 0.086
GAF, score mean (SD) 60.4 (12.5) 65.0 (11.4) 58.3 (13.4) 54.0 (10.5) 0.003†
†a > c, p-value = 0.004. post-hoc analysis.
MADRS, Montgomery–Asberg Depression Rating Scale’ GAF, Global Assessment of Functioning
doi:10.1371/journal.pone.0151417.t002
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had more negative symptoms than those with high PUFA levels [13]. In a study in drug naïve-
patients with schizophrenia, ω-3 PUFA deficiency was associated with negative symptoms
[14]. Accordingly, it was demonstrated that supplementation with ω-3-rich fish oil might result
in a significant improvement in negative but not in positive symptoms of patients with schizo-
phrenia [36]. In a clinical trial of EPA supplementation in patients with schizophrenia, an
increase in membrane ω-3 PUFAs was significantly correlated with change in PANSS negative
symptom scores and total scores [37].
The prefrontal cortex plays an important role in higher brain functions. The basic activity of
this brain region is considered to be the orchestration of thoughts and actions in accordance
with internal goals [38]. It has also been implicated in planning complex cognitive behaviour,
executive function, decision making, and moderating social behaviour [39]. It has been
assumed that hypofunctioning of the cortical and prefrontal dopamine systems contributes to
cognitive impairment and negative symptoms in patients with schizophrenia, such as dimin-
ished emotional expression and avolition [40]. The relationship between ω-3 PUFA deficiency
and negative symptoms is concordant with the dopamine hypothesis of schizophrenia. In
Table 3. Comparison of erythrocyte membrane phosphatidylethanolamine lipids levels according to dominance of positive or negative
symptoms.
Subtypes
Positive dominant[a]
(N = 38)
Mixed[b]
(N = 23)
Negative dominant[c]
(N = 19)
p
value
Post-hoc analysis(Bonferroni
correction)
Myristic acid (14:0) 0.59 (0.21) 0.54 (0.16) 0.48 (0.15) 0.102
Palmitic acid (16:0) 23.64 (3.16) 23.97 (2.04) 22.45 (2.41) 0.168
Margaric acid (17:0) 2.50 (0.55) 2.27 (0.67) 1.94 (0.50) 0.004 a>c**
Stearic acid (18:0) 12.04 (2.36) 12.99 (2.52) 12.14 (1.85) 0.278
Oleic acid (18:1n-9) 22.96 (2.58) 23.08 (2.56) 24.07 (3.57) 0.366
Eicosenoic acid (20:1n-9) 0.76 (0.31) 0.92 (0.38) 1.24 (0.40) < 0.001 a<c***, b<c*
Mead acid (20:3n-9) 0.11 (0.50) 0.12 (0.47) 0.13 (0.40) 0.313
Erucic acid (22:1n-9) 0.65 (0.91) 1.04 (1.01) 1.38 (0.78) 0.017 a<c*
Nervonic acid (24:1n-9) 0.06 (0.02) 0.05 (0.02) 0.05 (0.15) 0.219
Linoleic acid (18:2n-6) 6.26 (0.69) 5.91 (0.79) 6.69 (2.26) 0.142
r-Linolenic acid (18:3n-6) 0.33 (0.13) 0.41 (0.16) 0.45 (0.14) 0.008 a<c**
Dihomo-γ-linolenic acid (20:3n-6) 1.61 (0.42) 1.62 (0.43) 1.70 (0.34) 0.722
Arachidonic acid (20:4n-6) 15.95 (2.11) 14.95 (2.04) 15.35 (2.02) 0.180
Docosadienoic acid (22:2n-6) 0.06 (0.05) 0.10 (0.04) 0.11 (0.04) <0.001 a<c***, a<b*
Adrenic acid (22:4n-6) 4.69 (0.71) 4.61 (1.10) 4.78 (0.82) 0.824
a-Linolenic acid (18:3n-3) 0.19 (0.05) 0.21 (0.08) 0.19 (0.43) 0.543
Eicosapentaenoic acid (20:5n-3) 0.50 (0.17) 0.49 (0.17) 0.43 (0.13) 0.270
Docosapentaenoic acid (22:5n-3) 2.25 (0.36) 2.18 (0.53) 2.02 (0.37) 0.150
Docosahexaenoic acid (22:6n-3) 2.83 (0.80) 2.51 (0.73) 2.36 (0.50) 0.050
Sum of monounsaturated fatty acids 26.45 (3.01) 27.13 (2.98) 28.78 (3.11) 0.027 a<c*
Sum of polyunsaturated fatty acids 34.79 (3.30) 33.10 (3.48) 34.22 (2.42) 0.138
Sum of n-6 fatty acids 28.90 (2.72) 27.60 (2.80) 29.09 (2.19) 0.113
Sum of n-3 fatty acids 5.77 (1.09) 5.39 (1.31) 5.00 (0.76) 0.043 a>c*
n-6 to n-3 fatty acids ratio 5.13 (0.80) 5.38 (1.23) 5.94 (1.00) 0.018 a<c*
* p-value < 0.05
** p-value < 0.01
*** p-value < 0.001
doi:10.1371/journal.pone.0151417.t003
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animal studies, deficiencies in ω-3 PUFAs have been found to cause reductions in levels of
dopamine and D2 receptors in the frontal cortex [41,42] and a hypofunction of the prefrontal
dopamine system, reflecting a correlate of negative symptoms and cognitive impairments [6].
In addition, ω-3 PUFA deficiency of rats affects dopaminergic neurotransmission and mRNA
expression of D2 receptor genes in the frontal cortex [43–45].
Animal studies showed that oral intake of ω-3 FAs can increase and decrease the number of
D2 receptors in the frontal lobe and striate body, respectively [46,47]. In a clinical trial of
patients with first-episode schizophrenia, improvement of negative symptoms induced by
ethyl-EPA supplementation was associated with metabolic brain changes, particularly increases
in glutathione [48]. Glutathione is an antioxidant that protects dopaminergic neurons from
oxidative and excitatory damage [49,50].
White matter changes including dysregulated myelination are presented in patients with
schizophrenia [51]. Reduced levels of PUFAs in erythrocyte membranes may be also related to
white matter integrity throughout various brain areas including the frontal lobe. An imaging
study of patients with early psychosis found that more severe negative symptoms were associ-
ated with lower levels of integrity in the white matter associated with total PUFA or arachi-
donic acid (an ω-6 PUFA), whereas no significant associations were found with positive
symptoms [52]. Furthermore, animal studies suggested that PUFAs are important for the
development, structure, and functioning of neurons and glial cells [53] and for neurite out-
growth, exocytosis, and monoaminergic signal transmission [54]. Thus, PUFA deficiency may
impair dopaminergic and glutamatergic neurotransmission in the frontal lobe, which is linked
to the negative symptoms of schizophrenia [13]. These biochemical, imaging, pharmacological,
and animal experimental studies support our findings.
In particular, nervonic acid, a major constituent of myelin membranes, helps to maintain
white matter integrity [52,55]. In the present study, nervonic acid was negatively correlated
with scores of the PANSS (total score and scores on the three subscales) in UHR individuals,
which is consistent with earlier studies of patients with schizophrenia.
Myristic acid is an anchorage moiety, and plays a role in attaching proteins to lipid biomem-
branes. Linkage of myristic acid to proteins is called myristoylation. It is involved in key cellular
functions including apoptosis, cellular differentiation and intracellular signalling. Myristic acid
is vulnerable to redox damage and can be rendered immunogenic when oxidised [56].
In a previous study of patients with schizophrenia, Sethom observed a decrease in the levels
of ω-6 (arachidonic acid) and ω-3 (DHA) PUFAs but an increase in the ω-6:ω-3 ratio [14]. The
higher ω-6:ω-3 PUFA ratio may be indicative of a pro-inflammatory response [57,58]. How-
ever, a stronger inflammatory response may increase the production of free radicals and reduce
PUFA levels [59]. Reduced anti-inflammatory activity may be implicated in the negative symp-
toms and cognitive impairment observed during the acute stages of schizophrenia episodes
[60]. Our finding of a higher ω-6:ω-3 ratio related to negative symptoms is consistent with pre-
vious research.
Among ω-9 MUFAs, eicosenoic acid and erucic acid (its elongation product) was correlated
with negative symptoms and were higher in the negative-symptoms-dominant group. Eicose-
noic acid was recently reported as a key biomarker for schizophrenia in a large global metabolic
profiling study [61]. Serum eicosenoic acid levels were significantly higher in patients with
schizophrenia, prior to antipsychotic treatment than in healthy controls [61]. Elevated eicose-
noic acid (together with other observed metabolic abnormalities) may reflect increased FA
catabolism as an alternative energy source, resulting from insufficient mitochondrial glycolytic
energy generation in the brain [62]. The present findings indicate that such metabolic abnor-
malities occur in UHR individuals prior to schizophrenia, particularly in relation to negative
symptoms. Increased levels of eicosenoic and/or erucic acid have also been reported in the
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brains of rats with cerebral ischemia [63], in cognitively impaired elderly people [64], and in
children with regressive autism [65]. These observations suggest that increases in ω-9 FAs may
be associated with central nervous system dysfunction [66].
Negative symptoms generally begin prior to schizophrenia onset and are regarded as a more
primary psychopathology [67]. Indeed, the disability of patients with schizophrenia is associ-
ated primarily with negative symptoms. The negative symptoms of schizophrenia are less
responsive to antipsychotic treatment than the positive symptoms, and specific treatment for
negative symptoms is not yet available. Thus, our findings of an association between mem-
brane FAs and negative symptoms may help to improve our understanding of schizophrenia
and aid in the development of treatments for UHR individuals or patients with schizophrenia.
Further studies are needed to identify the specific types of symptoms that respond best to treat-
ment with ω-3 FA supplements.
Several limitations should be considered when interpreting these data. First, the sample size
was relatively small and there were a large number of fatty acids assessed; as such, these data
need to be regarded as exploratory, as there is a risk of both type 1 and 2 errors. Since all conse-
cutive referrals over a period of approximately 2 years were considered for inclusion the sample
is representative for UHR patients [17]. It is not known if the associations between alterations
in FAs and the severity of symptoms are attributed to primary factors (i.e. the neurobiology
underlying schizophrenia spectrum disorders) or secondary factors (i.e. altered dietary patterns
arising from altered disease-related behaviour). Use of a UHR cohort goes some way to reduc-
ing this confound.
Our findings suggest that abnormalities in FA metabolism may be associated with the
neurobiological etiology of psychopathology in UHR individuals. Alterations in membrane
FAs correlated with negative symptoms, which are primary psychopathological features of
schizophrenia and are closely associated with the long-term outcome of schizophrenia spec-
trum disorder. Membrane FAs could serve as useful biological markers for early stages of
schizophrenia; modulation of membrane FAs may provide a preventative intervention in sub-
jects at UHR for schizophrenia.
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